Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today…
Long-term investment holding acquires majority stake in market leader of innovative planning software for endoprosth…
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the a…
Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical…
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that…
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs pro…
Winner of the Australian Global Innovation Linkages Program Funding dedicated to advancing regenerative scaffolds for br…
Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidia…
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field…